Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Savara Inc. (SVRA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.1000-0.0200 (-1.79%)
At close: 4:00PM EST
Advertisement

Savara Inc.

Building III
Suite 200 6836 Bee Cave Road
Austin, TX 78746
United States
512 614 1848
http://www.savarapharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees27

Key Executives

NameTitlePayExercisedYear Born
Mr. Matthew PaulsChairman & CEO670.88kN/A1971
Mr. David L. LowranceCFO & Sec.563.2kN/A1968
Dr. Badrul A. Chowdhury M.D., Ph.D.Chief Medical Officer766.49kN/A1959
Ms. Kate McCabeSr. VP of Legal AffairsN/AN/AN/A
Ms. Anne EricksonSr. VP & Chief of StaffN/AN/AN/A
Dr. Dhaval Desai M.D.Head of Clinical Devel.N/AN/AN/A
Brian MaurerHead of Clinical OperationsN/AN/AN/A
Mr. Charles LaPreeSr. VP of Global Regulatory Affairs & Quality AssuranceN/AN/AN/A
Dr. Peter Clarke Ph.D.Exec. VP of Global Technical OperationsN/AN/A1960
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Corporate Governance

Savara Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement